The future of gene therapy depends on mastering in vivo delivery At the Advanced Therapies conference, industry leaders showcased how in vivo CAR T cell and gene delivery innovations could transform accessibility and clinical outcomes.

https://www.drugdiscoverynews.com/the-future-of-gene-therapy-depends-on-mastering-in-vivo-delivery-17102 Over the past decade, chimeric antigen receptor (CAR) T cell therapy has emerged as one of the most transformative innovations in cancer treatment, harnessing the immune system’s power to target and eliminate malignant cells. By redirecting patient-derived T cells to recognize specific antigens, CAR T therapies have achieved remarkable success in hematologic malignancies, particularly in refractory disease.